MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Clinical Trial ID NCT01097460

PubWeight™ 18.52^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01097460

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Treatment of HER2-positive breast cancer: current status and future perspectives.	Nat Rev Clin Oncol	2011	4.12
2	Targeted therapies for breast cancer.	J Clin Invest	2011	2.22
3	Dual targeting strategies with bispecific antibodies.	MAbs	2012	2.13
4	Regulation of ERBB3/HER3 signaling in cancer.	Oncotarget	2014	1.00
5	Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.	Biochim Biophys Acta	2014	0.96
6	IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.	MAbs	2011	0.93
7	Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer.	Int J Breast Cancer	2012	0.92
8	Bispecific antibodies and their applications.	J Hematol Oncol	2015	0.92
9	Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.	Oncologist	2014	0.89
10	A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.	Am J Transl Res	2015	0.83
11	Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions.	World J Clin Oncol	2014	0.82
12	Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.	Hum Vaccin Immunother	2015	0.81
13	Co-opting biology to deliver drugs.	Biotechnol Bioeng	2014	0.79
14	Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer.	Curr Breast Cancer Rep	2014	0.79
15	Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.	MAbs	2016	0.77